More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Siamycin I [164802-68-0]
Chemical Structure
Chemical Structure
Chemical Structure

Siamycin I [164802-68-0]

Research Use Only
AG-CN2-0146
AdipoGen Life Sciences
CAS Number164802-68-0
DownloadMSDS
Product group Chemicals
Estimated Purity>85%
Molecular Weight2163.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Siamycin I [164802-68-0]
  • Delivery Days Customer
    10
  • CAS Number
    164802-68-0
  • Certification
    Research Use Only
  • Estimated Purity
    >85%
  • Hazard Information
    Warning
  • Molecular Formula
    C97H131N23O26S4
  • Molecular Weight
    2163.5
  • Scientific Description
    Antibiotic [1]. Lariat peptide antiviral [1]. Anti-HIV and anti-HSV (Herpes simplex virus) agent [4-6]. Fsr quorum sensing inhibitor [7-9]. Calmodulin-activated myosin light chain kinase (MLCK) inhibitor [2, 3]. - Chemical. CAS: 164802-68-0. Formula: C97H131N23O26S4. MW: 2163.5. Isolated from Streptomyces sp. Antibiotic. Lariat peptide antiviral. Anti-HIV and anti-HSV (Herpes simplex virus) agent. Fsr quorum sensing inhibitor. Calmodulin-activated myosin light chain kinase (MLCK) inhibitor.
  • SMILES
    [H]OC(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]1([H])N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])N([H])C(=O)[C@@]2([H])N([H])C(=O)C([H])([H])N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]3([H])N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C3([H])[H])C([H])([H])SSC2([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])O[H])C([H])([H])SSC1([H])[H])C([H])([H])C(=O)N([H])[H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])[H])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])C([H])([H])[H])[C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization: M. Tsunakawa, et al.; J. Antibiot. 48, 433 (1995)
  • MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.--I. Isolation, structural determination and biological properties of MS-271: K. Yano, et al.; Bioorg. Med. Chem. 4, 115 (1996)
  • MS-271, A Novel Inhibitor of Calmodulin-Activated Myosin Light Chain Kinase from Streptomyces sp.--II. Solution Structure of MS-271: Characteristic Features of the 'Lasso' Structure: R. Katahira, et al.; Bioorg. & Med. Chem. 4, 121 (1996)
  • FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2',3'-dideoxynucleosides: H. Nakashima, et al.; Biol. Pharm. Bull. 19, 405 (1996)
  • Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor: P.F. Lin, et al.; Antimicrob. Agents Chemother. 40, 133 (1996)
  • Current Lead Natural Products for the Chemotherapy of Human Immunodeficiency Virus (HIV) Infection: E. De Clercq; Med. Res. Rev. 20, 323 (2000)
  • Siamycin Attenuates fsr Quorum Sensing Mediated by a Gelatinase Biosynthesis-Activating Pheromone in Enterococcus faecalis: J. Nakayama, et al.; J. Bacteriol. 189, 1358 (2007)
  • Two-component signal transduction as potential drug targets in pathogenic bacteria: Y. Gotoh, et al.; Curr. Opin. Microbiol. 13, 232 (2010)
  • Anti-HIV siamycin I directly inhibits autophosphorylation activity of the bacterial FsrC quorum sensor and other ATP-dependent enzyme activities: P. Ma, et al.; FEBS Lett. 585, 2660 (2011)